BYSI Quote, Financials, Valuation and Earnings

Electromed has a net margin of -- compared to BeyondSpring's net margin of 12.06%. BeyondSpring's return on equity of -- beat Electromed's return on equity of 16.57%.

BeyondSpring has a consensus price target of --, signalling downside risk potential of -60.57%. On the other hand Electromed has an analysts' consensus of $38.00 which suggests that it could grow by 85.1%. Given that Electromed has higher upside potential than BeyondSpring, analysts believe Electromed is more attractive than BeyondSpring.

BeyondSpring has a beta of 0.074, which suggesting that the stock is 92.566% less volatile than S&P 500. In comparison Electromed has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.159%.

BeyondSpring has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BeyondSpring pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

BeyondSpring quarterly revenues are --, which are smaller than Electromed quarterly revenues of $15.7M. BeyondSpring's net income of $4.5M is higher than Electromed's net income of $1.9M. Notably, BeyondSpring's price-to-earnings ratio is -- while Electromed's PE ratio is 25.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BeyondSpring is 29.97x versus 3.00x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -- compared to BeyondSpring's net margin of -35.24%. BeyondSpring's return on equity of -- beat Myomo's return on equity of -38.11%.

BeyondSpring has a consensus price target of --, signalling downside risk potential of -60.57%. On the other hand Myomo has an analysts' consensus of $9.15 which suggests that it could grow by 278.1%. Given that Myomo has higher upside potential than BeyondSpring, analysts believe Myomo is more attractive than BeyondSpring.

BeyondSpring has a beta of 0.074, which suggesting that the stock is 92.566% less volatile than S&P 500. In comparison Myomo has a beta of 1.489, suggesting its more volatile than the S&P 500 by 48.933%.

BeyondSpring has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BeyondSpring pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

BeyondSpring quarterly revenues are --, which are smaller than Myomo quarterly revenues of $9.8M. BeyondSpring's net income of $4.5M is higher than Myomo's net income of -$3.5M. Notably, BeyondSpring's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BeyondSpring is 29.97x versus 2.44x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -- compared to BeyondSpring's net margin of -2201.34%. BeyondSpring's return on equity of -- beat VolitionRX's return on equity of --.

BeyondSpring has a consensus price target of --, signalling downside risk potential of -60.57%. On the other hand VolitionRX has an analysts' consensus of $2.93 which suggests that it could grow by 219.57%. Given that VolitionRX has higher upside potential than BeyondSpring, analysts believe VolitionRX is more attractive than BeyondSpring.

BeyondSpring has a beta of 0.074, which suggesting that the stock is 92.566% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.072, suggesting its more volatile than the S&P 500 by 7.247%.

BeyondSpring has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BeyondSpring pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

BeyondSpring quarterly revenues are --, which are smaller than VolitionRX quarterly revenues of $246.4K. BeyondSpring's net income of $4.5M is higher than VolitionRX's net income of -$5.4M. Notably, BeyondSpring's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BeyondSpring is 29.97x versus 63.41x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -- compared to BeyondSpring's net margin of 0.18%. BeyondSpring's return on equity of -- beat Xtant Medical Holdings's return on equity of -26.62%.

BeyondSpring has a consensus price target of --, signalling downside risk potential of -60.57%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 192.15%. Given that Xtant Medical Holdings has higher upside potential than BeyondSpring, analysts believe Xtant Medical Holdings is more attractive than BeyondSpring.

BeyondSpring has a beta of 0.074, which suggesting that the stock is 92.566% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.181, suggesting its less volatile than the S&P 500 by 118.091%.

BeyondSpring has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BeyondSpring pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

BeyondSpring quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $32.9M. BeyondSpring's net income of $4.5M is higher than Xtant Medical Holdings's net income of $58K. Notably, BeyondSpring's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BeyondSpring is 29.97x versus 0.67x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.